Skip to main content

Table 11 Selected studies for AML therapy from 2020 ASH annual meeting

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Abstract #

Authors (reference)

Study agents

Phase

NCT

27

Wang et al. [131]

Gilteritinib

III

02752035

333

Daver et al. [136]

Gilteritinib, Venetoclax

Ib

03625505

461

Pollyea et al. [137]

Azacitidine, Venetoclax

Sub study of III and Ib

02203773

02993523

636

Stein et al. [138]

Enasidenib

Sub study of II

03013998

330

Sallman et al. [143]

Magrolimab

Ib

03248479

331

Aldoss et al. [144]

Flotetuzumab

I

02152956

460

Ravandi et al. [145]

Vibecotamab

I

02730312

165

Abedin et al. [146]

Lintuzumab Ac225

I

03441048